About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
To evaluate the expression (nuclear and cytoplasmatic) of PTOV1 , Notch and Wnt on TMAs in c different histological types of carcinomas with low and high grades of malignancy . To correlate the inmunoexpression with classical parameters of tumor behaviour : tumoral size, grade of malignancy, vascular permeation, lymph nodes metastasis in each histological subtype and demonstrated the role of PTOV1 as predictive molecular marker in carcinomas.
(Research Biomedical Unit)
IP: Inés de Torres Ramirez
Studying in colorectal cancer mechanisms of action of the central signal transduction pathways, identify potential molecular alterations that can be used as therapeutic targets and characterize the degree of genetic inestability.
IP: Santiago Ramon y Cajal Agüeras
We have characterized the levels of activation in Cell Signalling in a spectrum of solid tumors and correlated the levels of various factors, including mTOR and downstream proteins (p70S6K, S6, 4EBP1, eIF4E) with prognosis and grade of malignancy. Also, are being characterized, at the molecular level, the factors involved in controlling the translation cap dependent and independent in malignant tumors.
The expression of mARN genes identified by Dr.R. Bernards has been studied in normal and tumor tissue of cancer patients. This study identifies for the first time, RSK4 and KIAA0828 genes as genes whose role may be relevant in cancer. The expression of these genes is being studied in protein by Western blot and immunohistochemistry. Also are characterizing the biochemical pathways where these genes may be involved.
IP: Susana Gómez Olles Collaborators: Joel Rosado Rodríguez, Manuel López Meseguer, Berta Saez Gimenez, Irene Sansano Valero Funding agency: Ministerio Ciencia, Innovación y Universidades Funding: 148948.4 Reference: CPP2024-011409 Duration: 01/10/2025 - 30/09/2028
IP: Maria Jose Soler Romeo Collaborators: Alejandra Gabaldon Dominguez, Marc Patricio Liebana, Sheila Bermejo Garcia Funding agency: Sociedad Española de Nefrología (S.E.N.) Funding: 24000 Reference: SENEFRO/AYUDAS.INVEST/2025/SOLER Duration: 01/12/2025 - 30/11/2027
IP: Valeria Tubita Collaborators: Francesc Xavier Serra Marin, Eva Colas Ortega, Antonio Gil Moreno, Marta Rebull Santamaria, Lourdes Elena Salazar Huayna Funding agency: Asociación Española Contra el Cáncer Funding: 8539.84 Reference: SNRGS259715TUBI Duration: 01/12/2025 - 30/11/2027
IP: Matilde Lleonart Pajarin Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, David Virós Porcuna, Josep Castellví Vives, María Garrido Martínez, Pablo Verges Fort, Marina Bataller Fernández Funding agency: Fundación hna Funding: 50000 Reference: FUND.HNA/PREMI/LLEONART/2025 Duration: 01/10/2025 - 30/09/2027
The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
